Navigation Links
Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
Date:9/23/2011

BOSTON, Sept. 23, 2011 /PRNewswire/ -- Solos Endoscopy, Inc.'s (OTCPK: SNDY) is pleased to announce that the Company has launched a new website and will begin marketing its MammoView® Breast Endoscopy Components to hospitals across the Country through direct sales channels and social media.

MammoView® Instrument line contains 13 different Breast Endoscopy Components which are all featured on the Company's website http://www.solosendoscopy.com/newproductline.html.

The Solos MammoView® Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of the breast cancers arise.  Solos' intraductal devices are designed to provide direct observation with any endoscopic video system while providing unprecedented image quality, using advanced minimally invasive technologies and tissue preservation techniques.

The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

Sales of Breast Endoscopy Components for the period of June through August 2011 were $51,630, which represents a 32% increase from the prior year.  The Solos MammoView® instrument line is featured on the Company's new website www.solosendoscopy.com.

"We strongly believe in our MammoView® product line.  It is a key component for early breast cancer detection," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

CONTACT: Amanda Segersten, rsegersten@solosendoscopy.com


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
2. Solos Endoscopy to Reduce Debt by Over $620,000
3. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
4. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
5. Solos Endoscopy, Inc. To Launch New Corporate Website
6. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
7. Solos Endoscopy, Inc. To Introduce New Urology Instrument Line
8. Solos Endoscopy, Inc. Reports $34,291 in Sales Revenue for January 2011
9. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
10. Solos Endoscopy, Inc. Trends toward Strong Continued Growth in 2011
11. Solos Endoscopy, Inc. Announces Recapitalization Plan for 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has issued ... from extreme heat at their worksites. Employers with workers exposed to high ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
Breaking Medicine News(10 mins):